Moreover, the mechanism underlying its treatment of hyperlipidemia may be through regulating the PI3K/AKT/mTOR/SREBP‐1 pathway to inhibit de novo lipid synthesis. The gene discussed is SREBF1; the disease is hyperlipidemia.